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C1-inhibitor (C1-Inh) is a serine protease inhibitor
(serpin) with a unique, non-conserved N-terminal do-
main of unknown function. Genetic deficiency of C1-Inh
causes hereditary angioedema. A novel type of mutation
(3) in exon 3 of the C1-Inh gene, resulting in deletion of
Asp62-Thr116 in this unique domain, was encountered in
a hereditary angioedema pedigree. Because the domain
is supposedly not essential for inhibitory activity, the
unexpected loss-of-function of this deletion mutant was
further investigated. The 3 mutant and three addi-
tional mutants starting at Pro76, Gly98, and Ser115, lack-
ing increasing parts of the N-terminal domain, were pro-
duced recombinantly. C1-Inh76 and C1-Inh98 retained
normal conformation and interaction kinetics with tar-
get proteases. In contrast, C1-Inh115 and 3, which both
lack the connection between the serpin and the non-
serpin domain via two disulfide bridges, were com-
pletely non-functional because of a complex-like and
multimeric conformation, as demonstrated by several
criteria. The 3 mutant also circulated in multimeric
form in plasma from affected family members. The C1-
Inh mutant reported here is unique in that deletion of
an entire amino acid stretch from a domain not shared
by other serpins leads to a loss-of-function. The deletion
in the unique N-terminal domain results in a “multim-
erization phenotype” of C1-Inh, because of diminished
stability of the central -sheet. This phenotype, as well
as the location of the disulfide bridges between the ser-
pin and the non-serpin domain of C1-Inh, suggests that
the function of the N-terminal region may be similar to
one of the effects of heparin in antithrombin III, main-
tenance of the metastable serpin conformation.
The autosomal dominant disease hereditary angioedema
(HAE)1 is caused by functional deficiency of C1-inhibitor (C1-
Inh) (1). C1-Inh is the major inhibitor of C1s and C1r of the
classical pathway of complement and also an inhibitor of the
contact system proteases, factor XIIa, kallikrein, and factor XIa
(2–9). A lack of this inhibitor may result in recurrent episodes
of acute, local, circumscribed edema of the skin or mucosa. The
most serious and potentially life-threatening manifestation of
the disease is laryngeal edema (10). HAE is inherited as an
autosomal dominant trait; affected individuals are heterozy-
gous. Based on the relative levels of functional and antigenic
C1-Inh, two types of HAE have traditionally been described. In
type I ( 85% of HAE patients), defective expression of one
allele results in low antigenic and functional levels. In type II
(15% of HAE patients), levels of functional C1-Inh are low,
but C1-Inh antigen levels are normal because of the presence of
a dysfunctional mutant protein. Although heterozygosity
would suggest functional C1-Inh levels of around 50% in HAE,
these levels are lower than 50%, typically 5–30%, which is
ascribed to increased C1 activation and C1-Inh consumption
(10, 11). However, the description of low levels of non-func-
tional C1-Inh mutants in patients with type I HAE has dem-
onstrated that the distinction between types I and II HAE is
not absolute (12). For example, low levels of dysfunctional
mutant protein may occur in cases where the mutation also
leads to defective protein secretion (12, 13). Many different
mutations can lead to dysfunctional C1-Inh, as has recently
been reviewed (14).
C1-Inh is a human plasma glycoprotein and a member of the
serine protease inhibitor (serpin) family to which antithrombin
III (ATIII), plasminogen activator inhibitor 1, and 1-antitryp-
sin also belong. Serpins are suicide inhibitors that function as
a set mousetrap by forming highly stable complexes with their
cognate proteases. In its active form, a serpin has a metastable
structure with a flexible reactive site loop that protrudes from
the core of the molecule, the central -sheet. The key residues
P1-P1 form the reactive site, a pseudosubstrate for the target
protease. Upon proteolytic attack on this bond, the reactive site
loop is pulled into the central -sheet, inducing a dramatic
conformational change that results in the formation of covalent
complexes between inhibitor and protease (15, 16). Recent crys-
tallographic studies support the idea that during complex for-
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mation the catalytic triad of the protease becomes distorted,
which may explain the remarkable stability of the complex
(17–19). Because mutations in the conserved flexible hinge
region convert most inhibitory serpins into substrates, it is
currently believed that the velocity of this conformational
change determines whether complex formation and inhibition
occur or whether the serpin is cleaved and the protease re-
leased (20–24). Indeed, type II HAE may result from mutations
in this hinge region of C1-Inh (25, 26).
The conformational flexibility of serpins is also demon-
strated by the existence of additional, biologically relevant
conformations that are more stable. One of these is a latent,
inactive form, adopted naturally by plasminogen activator inhib-
itor 1 and ATIII, in which the uncleaved reactive site loop is
inserted into -sheet A, and the C-terminal peptide stalk and
strand 1C are reoriented along the side of the molecule (27, 28).
In ATIII and 1-AT this latent state can be artificially induced
(29), but artificial formation of latent C1-Inh has never succeeded
(30, 31). Secondly, non-covalent multimerization can occur upon
denaturation, heating, or proteolysis at certain sites in the reac-
tive site loop (32, 33). Also, several disease-associated mutants of
C1-Inh, ATIII, and 1-AT have this multimeric conformation
(15), in some cases leading to accumulation of huge intracellular
protein aggregates and loss of cellular function in diseases like
emphysema (reviewed by Lomas and Carrell, Ref. 34).
Point mutations causing spontaneous multimerization can
be located in diverse regions: in or near the hinge (29, 35, 36),
near a conserved hydrophobic pocket at the C terminus (13), in
helix B at a site predicted to play a role in the opening of
-sheet A (37, 38), and near helix F which overlies -sheet A
(39, 40). Conformational changes associated with latency or
multimerization may result from similar structural causes, as
demonstrated by ATIII-Rouen VI, in which a single point mu-
tation results in the formation of latent monomers or multim-
ers, depending on temperature (39).
Next to its canonical serpin domain, C1-Inh has a unique
N-terminal domain of 116 amino acids. Two disulfide bridges
linking cysteine 101 to cysteine 406 and cysteine 108 to cys-
teine 183 connect the N-terminal to the serpin domain (41).
Reduction of these disulfide bonds in the intact serpin reduces
its conformational stability and induces a latent conformation
by auto-insertion of the reactive site loop into the central A
-sheet (42). The N-terminal domain is unique for C1-Inh, and
its exact function is unknown. Its first 98 residues were shown
not to be essential for complex formation (43). Here, we de-
scribe a novel type of mutation in the C1-Inh gene that sheds
additional light on the function of this domain. The mutation,
detected in a Dutch HAE pedigree, involves a deletion of 165
base pairs in exon 3 of the C1-Inh gene, leading to loss of amino
acids 62 to 116. Although located in the non-serpin domain, the
deletion resulted in loss of functional C1-Inh. The unique fea-
tures of this pathological C1-Inh mutant prompted investiga-
tion of the structural basis for the phenotype. Unexpectedly,
the results revealed that the cysteine-containing fragment of
the N-terminal domain of C1-Inh stabilizes the serpin domain
by tethering the central -sheet via disulfide bridges. Thus, the
reactive site loop is prevented from spontaneous insertion,
reminiscent of one of the roles played by heparin in ATIII.
MATERIALS AND METHODS
Materials—[35S]Methionine and 14C-methylated protein markers
were obtained from the Radiochemical Center (Amersham Biosciences).
Biotin was from Pierce (Rockford, IL) and coupled to proteins according
to the manufacturer’s instructions. Purified human plasma C1-Inh was
a gift from Behringwerke (Marburg, Germany). Dithiothreitol and soy-
bean trypsin inhibitor were purchased from Sigma; N-ethylmaleimide
was purchased from BDH Biochemicals (Poole, UK). C1s for kinetic
assays was purchased from Calbiochem (La Jolla, CA). Human factor
XIIa and kallikrein were purchased from Kordia (Leiden, the Nether-
lands). Biotinylated polyclonal rabbit antibodies against human C1-Inh
and the monoclonal antibodies (mAb) RII (against human C1-Inh) and
Kok12 (specific for cleaved or complexed human C1-Inh) have been
described before (44, 45). C1s for ELISAs was purified and biotinylated
as described before (44). Streptavidin coupled to polymerized horserad-
ish peroxidase was obtained from Sanquin (Dept. of Immune Reagents,
Amsterdam, The Netherlands). Streptavidin coupled to monomeric
horseradish peroxidase was obtained from Amersham Biosciences.
Patient DNA Purification and Plasma Parameters—Blood samples
were collected in siliconized vacutainer tubes (BD PharMingen). Soy-
bean trypsin inhibitor (100 g/ml), benzamidine (10 mM), and EDTA (10
mM) were added to prevent in vitro activation of the complement and
contact systems. Tubes were centrifuged at 1,300  g for 10 min, and
plasma was aliquoted and stored at 70 °C until testing. Cells were
collected and genomic DNA was purified according to the high salt
precipitation protocol (46). Affected members were investigated for
C1-Inh and C4 as reported previously (47) or ELISAs were utilized as
described below.
PCR, Plasmid Construction, and Protein Expression—PCR on
genomic DNA (0.5 g) was performed with primers (0.5 M) flanking
exon 3 of the C1-Inh gene (28 cycles of 30 s, 90 °C; 60 s, 56 °C; 90 s,
72 °C). Forward primer, 5-CTGACTATCCCTCATCTTC-3; reverse
primer, 5-TTAGTGGCTGCGACCTTAT-3. 5-ends correspond with
nucleotides 1951 and 2947, respectively, of the published C1-Inh gene
sequence (48, 49). Wild-type and mutant PCR products were purified
from agarose gels, subcloned in a T-tailed vector (Promega), and two
independent clones were sequenced (USB, Cleveland, OH). Subcloning
of relevant fragments was done by digestion with BamHI and EcoNI
and insertion into the corresponding sites in the C1-Inh expression
plasmid (50). COS-1 cell transfection, metabolic labeling, immunopre-
cipitation, and SDS-PAGE were done as described before (13, 50). PCR
and subcloning for production of the N-terminal deletion mutants in
Pichia pastoris was performed as described. Primers were designed that
started at amino acid 76, 98, and 115 of C1-Inh according to the
numbering of Bock et al. (41) and enabled subcloning of the mutant gene
in the plasmid for expression and secretion by P. pastoris. Transforma-
tion of the P. pastoris strain GS115 and C1-Inh expression were per-
formed as described before (51).
SDS-PAGE and Western Blotting—Electrophoresis was performed
on Bio-Rad Mini Protean II and Hoefer SE600 systems. Immunopre-
cipitation of plasma samples or [35S]methionine-labeled COS media
was done with mAbs coupled to Sepharose 4B (Amersham Biosciences).
Western blotting of HAE and normal plasma was performed by first
adsorbing plasma samples (20 l) onto mAb RII-Sepharose overnight,
followed by five washes with phosphate-buffered saline containing 0.1%
(w/v) Tween 20 (PT) and dissociation of bound C1-Inh by boiling in
non-reducing sample buffer. Samples were electrophoresed on 7.5% gels
and transferred to nitrocellulose. Blots were blocked with 0.4% (w/v)
skimmed milk powder in phosphate-buffered saline and incubated with
rabbit polyclonal anti-C1-Inh antibodies (2 g/ml) for 2 h, followed by a
1-h incubation with peroxidase-conjugated horse polyclonal anti-rabbit
antibodies (1:1000, Sanquin). Blots were developed with chemolumines-
cence reagents from Amersham Biosciences.
Reduction and Alkylation of C1-Inh—Plasma C1-Inh (1 mg/ml) was
incubated for 30 min at room temperature with 100 mM dithiothreitol
and subsequently with 250 mM N-ethylmaleimide to irreversibly alkyl-
ate the free cysteines. A control sample was treated with 250 mM
N-ethylmaleimide only. This preparation was dialyzed twice against a
100-fold excess of phosphate-buffered saline.
ELISAs—C1-Inh antigen was detected with an ELISA modified from
a radioimmunoassay (45, 52) as described earlier (53). Functional hu-
man C1-Inh was detected as described (54). Briefly, C1-Inh was bound
to solid-phase mAb RII against human C1-Inh and detected with bioti-
nylated C1s. Notably, this assay is an end-stage, and not a kinetic,
assay that measures the number of functional C1-Inh molecules rather
than the kinetics of the interaction between C1s and C1-Inh. Confor-
mationally changed C1-Inh was measured in an ELISA system with the
mAb Kok12 as coating antibody. This mAb reacts with neo-epitopes
exposed on complexed or cleaved C1-Inh. C1-Inh multimers were de-
tected in an ELISA with mAb RII both as coating and as detecting
antibody. PT was used as the buffer for all incubation steps in the
ELISAs.
Kinetics of the Interaction between C1-Inh and Target Proteases—The
interaction between C1-Inh and C1s, coagulation factor XIIa, or kal-
likrein was studied with the method of progress curves as described
before (55). Experiments were performed twice in triplicate with similar
results.
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Heat Stability—Culture supernatants containing normal or mutant
C1-Inh were incubated for 2 h at different temperatures, followed by
centrifugation at 10,000  g for 20 min. Antigen remaining in solution
was measured in an ELISA for C1-Inh antigen.
Sucrose Density Gradient Centrifugation—Plasma samples (200 l)
were loaded onto 5–25% (w/v) sucrose gradients in phosphate-buffered
saline and centrifuged at 35,000 rpm at 4 °C for 16 h. Fractions were
tested in ELISAs for C1-Inh antigen or multimers. Plasma fractions
were also tested for C1-Inh, IgG, and IgM on an automated nephelom-
eter (Behringwerke) as a reference for the molecular mass of C1-Inh
species.
RESULTS
C1-inhibitor Protein and DNA Sequence of the Patient—The
index patient had a typical history of HAE and was initially
classified as a type I HAE based on levels of functional and
antigenic levels of C1-Inh (17% both) and low C4 levels (30
mg/l). However, upon analysis by immune precipitation and
immunoblotting, plasma from a member of the affected family
appeared to contain low levels of an aberrant, low molecular
mass form of C1-Inh of about 70 kDa, which was smaller than
the intact and cleaved forms C1-Inh of 104 kDa and 97 kDa,
respectively, which naturally occur in human plasma (Fig. 1).
DNA sequencing of the pedigree, with primers flanking exon
3 of the C1-Inh gene, yielded an anomalous, specific PCR frag-
ment. In addition to the normal fragment of 997 base pairs, a
shorter fragment of 830 base pairs was observed that was
cloned and sequenced (Fig. 2, a and b; GenBankTM AY291075).
It appeared that a deletion of 165 base pairs within the coding
sequence of exon 3 had occurred. As is virtually always the case
in HAE, the index patient was heterozygous for this deletion
(Fig. 2a). Exon 3 of the C1-Inh gene codes for part of the signal
sequence, the entire NH2-terminal domain, and part of the
serpin domain of C1-Inh. The deleted part is peculiar in nucle-
otide (27% A, 44% C, 12% G and 16% T) sequence. Many
A/C-rich direct repeats of up to 11 nucleotides are present,
which may have caused the deletion to occur. In addition, it
contains Cys101 and Cys108, which connect the N-terminal do-
main to the serpin domain by forming disulfide bridges with
Cys183 and Cys406 (41). This deletion of 165 base pairs pre-
dicted a deletion of 55 amino acids of the N-terminal non-serpin
domain, including two cysteines involved in the formation of
the two disulfide bridges of the molecules. This mutant is
further indicated as the 3 mutant.
Expression and Activity of C1-Inh Mutants—In the first in-
stance it seemed unclear why the in-frame deletion identified
in the patient should cause HAE; it is located outside the serpin
domain, and earlier studies have indicated that the N-terminal
domain is dispensable for inhibitory capacity (43). An explana-
tion could be that the deletion severely impedes secretion,
thereby explaining the type I form of HAE. Expression of the
3 mutant in COS cells indicated, however, that the mutant
was in fact secreted, albeit at lower levels than WT C1-Inh but
unable to form complexes with C1s. This suggested a disturbed
functional interaction as the basis for disease, which is mostly
associated with type II HAE. To assess in detail this impaired
function of the N-terminal domain at a protein level, we de-
cided to express and analyze several additional N-terminal
deletion mutants, starting at amino acid 76, 98, and 115 (C1-
Inh76, C1-Inh98, and C1-Inh115 respectively, summarized in
Fig. 2c). To obtain sufficient amounts of recombinant protein
for a detailed analysis of the inhibitory and kinetic properties of
the N-terminal deletion mutants, we produced WT, C1-Inh76,
C1-Inh98, and C1-Inh115 in P. pastoris. In a previous study we
have shown that WT C1-Inh can be conveniently expressed in
this system and is fully functionally active (50). The proteins
were expressed at levels of 30, 35, 34, and 2 g/ml, respectively.
Supernatants of transfected cells or P. pastoris were ana-
lyzed by ELISA for C1-Inh antigen and function. It appeared
that the mutants 3 and C1-INH115 were completely non-
functional toward C1s (Fig. 3), whereas C1-Inh76 and C1-Inh98
displayed normal activity. Normal functional activity of the
latter two mutants was confirmed in the kinetic analysis show-
ing comparable association (kon) and dissociation (koff) con-
stants of these mutants with C1s, kallikrein, and factor XIIa as
WT C1-Inh (Table I). Thus, the decreased function of the 3
C1-Inh mutant likely was related to the absence of the linker
sequence between the serpin domain and the N-terminal
domain.
Heat Stability and Conformation of Normal and Mutant
C1-Inh—Functional serpins, including C1-Inh, are in a meta-
stable state that can be monitored by thermal unfolding of the
protein. Serpins in a native conformation will precipitate or
severely multimerize at elevated temperatures with concomi-
tant loss of detectable antigen. However, upon inactivation by
insertion of the reactive site loop into the central -sheet, a
serpin will remain soluble. Although WT C1-Inh and the two
N-terminal deletion mutants with intact disulfide bridges (C1-
Inh76 and C1-Inh98) were precipitated at 50–60 °C, C1-Inh115
and 3 remained detectable up to 80 °C (Fig. 4a). This indi-
cated that the latter two mutant proteins are in an intrinsically
stable conformation, as opposed to the metastable conforma-
tion of the wild-type protein. This was confirmed by the in-
creased reactivity of C1-Inh115 and 3 with mAb Kok-12 (which
recognizes a neo-epitope exposed on complexed and inactivated
C1-Inh) compared with WT, C1-Inh76, and C1-Inh98 C1-Inh.
Serial dilutions of C1-Inh were tested in the Kok-12 ELISA,
and C1-Inh115 and 3 displayed a profound reactivity with this
conformation-specific mAb (Fig. 4b). Notably, no reactivity of
these two mutants with the mAb KII, specific for the cleaved
form of C1-Inh, was observed (data not shown), which indicates
that the mutants were not conformationally changed because of
proteolytic cleavage of the reactive site loop.
Multimerization of Mutant C1-Inh in Vitro—Because in
other C1-Inh mutants the intrinsic exposure of the Kok-12
epitope and an increase in heat stability were associated with
spontaneous formation of non-covalent multimers (13, 35), WT
C1-Inh or deletion mutants were analyzed in an ELISA de-
signed to detect C1-Inh multimers. As can be observed in Fig.
5, the mutants 3 and C1-Inh115 indeed appeared to form
multimers in contrast with WT C1-Inh, C1-Inh76, and C1-
Inh98. Multimers of 3 could also be observed upon size frac-
tionation on sucrose gradients (results not shown). Together
with the reactivity with mAb Kok-12 and the increased heat
stability, these results suggested that the deletion mutant has
a conformation similar to several C1-Inh mutants described
previously, which was ascribed to overinsertion of the reactive
site loop and/or release of strand 1C, resulting in multimer
formation (13, 35).
FIG. 1. Low molecular mass C1-Inh is detected on SDS-PAGE
in affected HAE patient from a novel Dutch pedigree. Normal
(lane 2) and HAE plasma (lane 1) were absorbed onto RII-Sepharose,
and bound C1-Inh was subjected to non-reducing 7.5% SDS-PAGE.
After transfer to nitrocellulose, the blot was developed with polyclonal
anti-C1-Inh antibodies.
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Role of Disulfide Bridges in the Conformation of C1-Inh—
Because the deletion encompasses only Cys101 and Cys108, the
two remaining cysteines in the serpin domain might form a
novel disulfide bond, which given the location of Cys183 and
Cys406 would probably severely disturb the typical serpin con-
formation. To study the presence of disulfide bonds in the
mutant protein, the normal and mutant proteins were immu-
noprecipitated with mAb RII and compared on reducing and
non-reducing SDS-PAGE. In Fig. 6a it can be seen that the
normal protein displayed a difference in apparent molecular
mass upon reduction; under reducing conditions it migrated
with an apparent molecular mass of 97 kDa, as has been
observed before (e.g. Refs. 56, 57). The deletion mutant mi-
grated at identical molecular mass under both conditions, and
FIG. 2. A mutation in exon 3 of the
C1-Inh gene deletes Asp62-Thr116 in
the N-terminal, non-serpin domain of
C1-Inh. a, PCR analysis of genomic DNA
of HAE patients with primers flanking
exon 3 of the C1-Inh gene. Lanes 1 and 2
contain duplicate samples from an af-
fected member of the family under inves-
tigation. Lanes 3 and 4 represent an un-
related HAE patient, displaying only the
expected fragment at 997 base pairs. The
left lane contains a molecular mass
marker at 100-base pair increments. b,
the nucleotide and derived amino acid se-
quence of exon 3 of the C1-Inh gene. The
serpin domain starts at His114. Bold num-
bers indicate amino acid residues accord-
ing to Bock et al. (41). The boxed area
encloses the deletion of 165 base pairs
found in this HAE pedigree. Repeats of
the Glu-Pro-Thr-Thr sequence are doubly
underlined. The cysteines at positions 101
and 108 are indicated with bold italics.
c, schematic representation of four differ-
ent recombinant C1-Inh deletion mu-
tants. The gray right part of each mutant
represents the serpin domain of C1-Inh.
The part of the N-terminal domain pres-
ent in the various mutants is shown by
white bars on the left. A dotted line repre-
sents the linkage between Thr61 and
Glu117 in 3. The disulfide linkage config-
uration in WT C1-Inh is indicated by
dashed lines at the top.
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no disulfide-linked dimers could be observed (Fig. 6a, lanes 2
and 4), strongly arguing against the presence of novel intra- or
intermolecular disulfide bonds.
Another possibility is that the absence of disulfide bridges
itself caused the observed multimerization phenotype. We in-
deed validated that permanent disruption of the disulfide
bridges in normal C1-Inh by reduction and subsequent alkyla-
tion led to intrinsic conformational changes, as evidenced by
formation of C1-Inh multimers. Shown in Fig. 6b is the exten-
sive multimer formation at 37 °C for reduced/alkylated C1-Inh,
whereas treatment with only alkylating reagent did not induce
this state.
Conformation of Mutant C1-Inh in Vivo—To confirm the
properties of the C1-Inh mutants, observed in vitro, in the
naturally occurring situation, normal plasma and HAE plasma
containing the deletion mutant were analyzed by size on su-
crose gradients. To decrease the chance of activation and/or
multimerization in vitro, for these experiments samples were
used that had not been thawed previously. The fractions were
tested in ELISAs for C1-Inh antigen and multimers (Fig. 7).
Normal plasma displayed one peak in the C1-Inh antigen as-
say, and no multimers were detected by ELISA. The plasma of
the patient showed, in addition to a peak at the normal posi-
tion, one or more peaks at fractions corresponding to higher
molecular mass. Furthermore, only the patient plasma yielded
a response in the multimer ELISA, at fractions corresponding
to high molecular mass C1-Inh. Thus, the deletion mutant of
C1-Inh is also secreted in vivo and circulates in a form that is,
at least partially, multimeric.
DISCUSSION
Previously, we have described single-residue mutations in
C1-Inh from HAE patients that cause a conformational change
involving the reactive site loop and result in spontaneous mul-
timer formation (13, 35) and/or dysfunction (40). Such point
mutations, also observed in 1-AT and ATIII (29, 36–38), are
distributed over various regions of the serpin domain of C1-Inh
(15). The mutation described here is peculiar, because it is not
a point mutation of a highly conserved residue but a deletion of
55 residues in a domain that is unique for C1-Inh among the
serpins. To investigate the effect of this deletion we produced
several recombinant mutants, illustrated in Fig. 2c. While de-
letion of the majority of this domain, i.e. up to 97 amino acid
residues, had no effect on C1-Inh function, a deletion including
the disulfide bridges of this part completely disrupted C1-Inh
activity. Our observations may help understanding of the con-
formational changes involved in C1-Inh function and the role of
the N-terminal domain, including the cysteines that connect
the serpin and the unique non-serpin domains in C1-Inh.
The phenotype of the C1-Inh mutant of the patient was a
multimerization phenotype with no inhibitory activity. The 3
mutant as well as C1-Inh115 both displayed strongly enhanced
reactivity in a multimer ELISA with a homologous sandwich of
mAb RII (Fig. 5) and in an ELISA with mAb Kok-12 that reacts
with neo-epitopes exposed on complexed or proteolytically
cleaved C1-Inh (Fig. 4b). In other studies we have shown that
the epitope for mAb Kok12 is also expressed on C1-Inh mul-
timers (13). Notably, patient plasma contained circulating 3
multimers, as demonstrated with a sucrose gradient and a
multimer ELISA (Fig. 7), ruling out that the observed multim-
ers of the recombinant mutants were because of in vitro
artifacts.
The affected members of the pedigree with the 3 C1-Inh
mutant were described as type I HAE, based on their low
C1-Inh antigen levels. This seems surprising when the effect on
C1-Inh is considered to yield a dysfunctional protein, typically
found in type II HAE. We hypothesize that the decreased levels
of C1-Inh antigen leading to the diagnosis type I instead of type
II result from varying mechanisms, including impaired secre-
tion of the mutant protein. During recombinant expression of
the C1-Inh115 and 3 mutants we observed consistently lower
expression levels than for WT C1-Inh or the functional N-
terminal deletion mutants. Metabolic labeling studies in COS
cells were attempted without success to demonstrate intracel-
lular localization, but multimers were detected in Western
blots with cell extracts (data not shown). This suggests intra-
cellular multimerization of these mutants in vitro as has been
described for other C1-Inh variants of the multimerization
phenotype (12, 13). However, the dysfunctional protein was
also detected, though at low levels, in the plasma of the patient
(Fig. 1). Although the clearance of serpin multimers in vivo has
not been studied, that of complexed or inactivated serpins is
increased compared with that of native serpins (54). Because
C1-Inh multimers expose similar epitopes as complexes, as is
demonstrated by the reactivity of mAb Kok12 (13), the clear-
ance mechanism via the low density lipoprotein receptor-re-
lated protein might be similar (58). This has in fact been
experimentally supported by studies of Chang (59), who dem-
onstrated competition between 1-AT and ATIII complexes
versus multimers for binding to the low density lipoprotein
receptor-related protein. Hence, increased clearance of the dys-
functional mutant may have contributed to the apparent type I
HAE phenotype.
The explanation for the observed multimerization phenotype
can be the absence of the unique N-terminal domain and/or the
absence of disulfide linkage between the N-terminal and the
serpin domain. In a previous study (43), complex formation of
truncated variants lacking amino acid 1–98 displayed the ca-
pacity to form complexes with several target proteases that
were stable for at least 30 min. To fully appreciate the conse-
quences of the mutations, however, kinetic data are essential
because complex formation does not necessarily imply full func-
tional activity. Production of C1-Inh98 and C1-Inh76 in the
P. pastoris system yielded sufficient amounts of mutants for
such detailed kinetic studies. We have shown before that WT
C1-Inh from P. pastoris has similar kinetic properties as plas-
ma-derived C1-Inh (51). Association and dissociation constants
of the C1-Inh98 and C1-Inh76 mutants were essentially the
same as for WT C1-Inh (see Table I). This definitely ruled out an
essential role for the first 98 amino acids in inhibitory capacity of
C1-Inh. It can, however, be postulated that the presence of the
remaining part of the N-terminal domain of the 3 mutant pre-
vents correct folding or function of the serpin domain. For that
reason we produced C1-Inh115, which lacks the entire N-terminal
domain and consists solely of the serpin domain. This mutant
appeared to have the same phenotype as the 3 mutant identi-
fied in the patient. This observation pointed to the absence of
residues 99 to 115 as the explanation for the phenotype of the 3
FIG. 3. C1-Inh115 and 3 mutants do not form complexes with
C1s. Culture supernatants containing C1-Inh76, C1-Inh98, C1-Inh115,
3 mutants, or WT C1-Inh were absorbed onto solid-phase mAb RII and
incubated with biotinylated C1s. Functional activity was expressed as a
percentage of activity in normal human plasma.
C1-Inh Metastability Depends on Unique N-terminal Domain 29467
 at W
A
LA
EU
S LIBRA
RY
 on M
ay 4, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
mutant rather than folding abnormalities induced by the remain-
ing part of the N-terminal domain.
A feasible explanation for the observed inactivity is the dis-
ruption of the disulfide bridges between Cys183 and Cys406 in
the serpin domain with, respectively, Cys108 and Cys101 in the
non-serpin domain. This may have at least two different ef-
fects. First, the conformational change could result from a
novel disulfide bond between the remaining cysteines in the
serpin domain, but SDS-PAGE analysis did not reveal a differ-
ence in migration under reducing and non-reducing conditions
(Fig. 6a). Because the effect of reduction and alkylation of
plasma C1-Inh was similar to the effect of deletion of the two
N-terminal cysteines (Fig. 6b) (42, 60),2 it is most likely that
the absence of the disulfide linkage between the two domains
had caused the inactivity of the 3 mutant rather than the
2 D. Roem and E. Eldering, unpublished observations.
TABLE I
Association (Kon) and dissociation (Koff) rate constants of C1-Inh with various target proteases, as determined with progress curves
Protease
WT C1-Inh C1-Inh76 C1-Inh98
Kon  (M
1 s1) Koff Kon  (M
1 s1) Koff Kon  (M
1 s1) Koff
Cls 6.3  104 2.3  105 6.5  104 2.5  105 4.4  104 1.0  105
Kallikrein 8.2  103 2.1  105 5.9  103 3.5  105 3.9  103 1.0  105
XIIa 5.7  103 1.4  105 5.2  103 1.0  106 1.6  103 1.2  105
FIG. 4. C1-INH115 and 3 C1-Inh display a stable conformation.
a, heat stability. WT, C1-Inh76, C1-Inh98, C1-Inh115, and 3 C1-Inh
were incubated for 2 h at the indicated temperatures, centrifuged for 20
min at 10000  g, and the supernatant was analyzed in the ELISA for
C1-Inh antigen. b, C1-Inh preparations were analyzed in ELISA with
Kok-12 as catching antibody. The detection of Kok-12 reactive C1-Inh
was plotted against the C1-Inh concentration. Experiments were per-
formed three times with similar results.
FIG. 5. 3 mutant forms multimers in vitro. The presence of
C1-Inh multimers in supernatants containing WT C1-Inh or C1-Inh
mutants was analyzed in a sandwich ELISA with mAb RII as both
catching and detecting antibody. The detection of multimers is plotted
against the C1-Inh concentration. The experiment was performed three
times with similar results.
FIG. 6. Role of disulfide bonds in the conformation of C1-Inh. a,
absence of two cysteines does not lead to intra- or intermolecular
disulfide bond formation. Normal (lanes 1 and 3) and mutant (lanes 2
and 4) C1-Inh from metabolically labeled transfection media were im-
munoprecipitated with mAb RII and analyzed under non-reducing
(lanes 1 and 2) or reducing (lanes 3 and 4) conditions on 10% SDS-
PAGE. b, disruption of disulfide bonds in plasma C1-Inh causes mul-
timerization. Control C1-Inh (lane 1 and 2) or reduced/alkylated C1-Inh
(lane 3 and 4) was incubated for 2 h at 37 °C (lane 1 and 3) or 60 °C (lane
2 and 4)at a concentration of 1 mg/ml. Samples were analyzed by 4–15%
native PAGE.
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presence of an intra-serpin domain disulfide bond. This inter-
pretation is entirely in line with earlier results demonstrating
that disruption of the disulfide bridges in full-length C1-Inh
results in the formation of a latent, inactive conformation (59).
Our results demonstrating the crucial role of residues 99 to 115
underline the importance of the disulfide bonds in the stabili-
zation of the active conformation of C1-Inh. The crucial role of
the cysteines for serpin metastability is surprising because
these residues are not conserved among the serpins.
We have previously put forward a 3-dimensional model of the
serpin domain of C1-Inh based on homology with the crystal
structures of four native serpins (14). Comparison of the posi-
tions of the disulfide bonds in this model (Fig. 8a) with the
structure of ATIII complexed to a pentasaccharide reveals an
interesting homology (Fig. 8b) (61). Native ATIII has a flexible
central -sheet with the reactive site loop partly inserted. Bind-
ing of a pentasaccharide closes the central -sheet, thereby
stabilizing the metastable conformation and expelling the re-
active site loop, resulting in potentiation of ATIII. Moreover, it
is known that the presence of the pentasaccharide inhibits
spontaneous auto-insertion of the reactive site loop of ATIII
(61). The heparin-binding region on ATIII is located in the
same region as Cys183 in C1-Inh (42). This suggests that the
N-terminal domain of C1-Inh linked via disulfide bridges to the
serpin domain has a similar function as heparin for ATIII,
which is stabilization of the central -sheet to maintain the
metastable conformation. Notably, ATIII without heparin is
less stable than C1-Inh and latent ATIII is observed in plasma,
whereas latent C1-Inh has never been observed in vivo or in
vitro (28). Several other mutations leading to HAE support the
importance of this region for the metastable conformation of
C1-Inh. First, mutation of the residues Gly162 3 Glu/Arg and
Thr169 3 Pro leads to type I HAE (62, 63). These residues are
located between Cys183 and Cys406, and their mutation might
also affect stability of the central -sheet. Secondly, mutation
of Cys183 3 Tyr leads to type I HAE (63). The second cysteine
in the serpin domain of C1-Inh (Cys406) is located at the same
site as the disulfide bridge that links the short N-terminal
domain of ATIII to the serpin domain (Cys21 to Cys95). This
suggests that the terminal part of the unique N-terminal do-
main of C1-Inh is located at a similar position as the short
N-terminal domain of ATIII. Taken together these data
strongly suggest that the role of the disulfide bridges in C1-Inh
is similar to that of heparin binding for ATIII. However,
whereas the activity of ATIII is functionally regulated by hep-
arin at these sites, active conformation of C1-Inh would be
constitutively primed by the geometrical constraints imposed
by the disulfide bridges in the context of residues 99 to 115 of
its N-terminal domain. The inhibitory activity of C1-Inh, en-
hanced by heparin and other highly negatively charged poly-
mers (64, 65), must therefore be potentiated through a different
mechanism than that of ATIII.
CONCLUSIONS
A novel pathological C1-Inh mutant with a deletion of 55
amino acids in the unique N-terminal domain of C1-Inh was
identified. Studies of a recombinant variant of this mutant and
N-terminal deletion mutants starting at amino acids 76, 98,
and 115 indicated that C1-Inh115 and 3 C1-Inh displayed a
conformational change leading to multimerization, whereas
C1-Inh76 and C1-Inh98 displayed a wild-type-like conformation.
The 3 C1-Inh and the C1-Inh115 mutants were dysfunctional
FIG. 7. Presence of C1-Inh multimers in vivo. Samples (200 l) of
normal (NP, closed symbols) or mutant HAE (D3, open symbols) plasma
were layered onto 5–25% sucrose gradients. Fractions were analyzed in
C1-Inh antigen (circles) and multimer (triangles) ELISA. For C1-Inh
antigen ELISA, NP fractions were diluted 1:100, D3 fractions were
diluted 1:50, and the dilution for the multimer ELISA was 1:25. The IgG
peak as determined by nephelometric analysis was in fraction 27.
FIG. 8. Structure of C1-Inh compared with that of ATIII-pen-
tasaccharide complex. a, homology model of C1-Inh based on the
crystal structure of four different active serpins (14). The N-terminal
Thr116 and the two cysteines in the serpin domain are indicated as
ball-and-stick and labeled. b, crystal structure of ATIII bound to a
pentasaccharide (1AZX (61) from the Protein Database (www.rcsb.org/
pdb/) viewed in WebLabViewerLite (www.msi.com)). Phe121 and Cys95
of ATIII, at the same location as Cys183 and Cys406 of C1-Inh, are
indicated as ball-and-stick and labeled. The pentasaccharide is also
indicated as ball-and-stick and labeled.
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because the absence of the disulfide bridges between the serpin
and the unique N-terminal domain led to destabilization of the
metastable conformation of the serpin domain. This stabilizing
function of the N-terminal domain of C1-Inh resembles that of
heparin for ATIII. Thus, a broader perspective is offered for
understanding aberrant protein folding and/or multimeriza-
tion by intermolecular -sheet interactions, leading to pathol-
ogies which include HAE, emphysema, Alzheimer’s, and the
prion encephalopathies.
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